A research team led by Mario Daidone and Antonino Tuttolomondo from University Hospital, Policlinico, Paolo Giaccone, and the University of Palermo reported on Apr. 7 that treating acute decompensated heart failure patients with intravenous furosemide plus small-volume hypertonic saline solution resulted in reduced increases of certain inflammatory and remodeling biomarkers compared to treatment with furosemide alone.
The study matters because it explores a potential improvement in managing acute decompensated heart failure (ADHF), a condition marked by high rates of illness and death. Identifying therapies that can reduce harmful molecular markers could lead to better outcomes for these patients.
In this randomized trial published in Volume 18 of Aging-US, researchers enrolled 200 subjects with ADHF due to reduced ejection fraction. Of these, 107 received both i.v. furosemide and HSS while 93 received only i.v. furosemide. The results showed that those given the combination therapy had lower increases after saline load in biomarkers such as IL-6, hsTnT, sST2, galectin-3, NT-proBNP, as well as reduced expression of miR181b compared to those who received only the diuretic.
"Nevertheless, the possible effects of the i.v. furosemide + HSS treatment on natriuretic and inflammatory markers of heart failure deserve further confirmation, whereas the effects of this type of treatment on epigenetic signatures of pathologic mechanisms involved in the left ventricular dysfunction involved in AHF pathogenesis seem to be still not studied," said Daidone and Tuttolomondo.
The authors emphasized that their findings are based on a specific group within an ADHF population using a randomized design. They said more studies are needed to confirm whether these changes last over time or translate into improved clinical outcomes for patients with different types or stages of heart failure.
Looking ahead, future research may help clarify how adding small-volume hypertonic saline influences cardiac remodeling processes and miRNA regulation among larger groups facing acute or chronic forms of heart failure.
